

In the Claims

1-13. (Canceled)

14. (Previously presented) A method of treating Severe Acute Respiratory Syndrome (SARS) comprising the administration of a composition comprising an interferon (IFN) to an individual having SARS.

15. (Previously presented) The method according to claim 14, wherein said composition comprises an IFN in combination with an antiviral agent.

16. (Previously presented) The method according to claim 15, wherein said antiviral agent is Ribavirin.

17. (Previously presented) The method according to claim 14, wherein said IFN is recombinant human IFN-beta.

18. (Previously presented) The method according to claim 14, wherein said IFN is consensus interferon.

19. (Previously presented) The method according to claim 15, wherein said IFN is recombinant human IFN-beta.

20. (Previously presented) The method according to claim 15, wherein said IFN is consensus interferon.

21. (Previously presented) The method according to claim 14, wherein said IFN is a fused protein comprising at least an immunoglobulin domain.

22. (Previously presented) The method according to claim 15, wherein said IFN is a fused protein comprising at least an immunoglobulin domain.

23. (Previously presented) The method according to claim 17, wherein said IFN is a fused protein comprising at least an immunoglobulin domain.

24. (Previously presented) The method according to claim 18, wherein said IFN is a fused protein comprising at least an immunoglobulin domain.

25. (Previously presented) The method according to claim 14, wherein said IFN is administered at a dosage of about 1 to 50 µg per person per day, or about 10 to 30 µg per person per day or about 10 to 20 µg per person per day.

26. (Previously presented) The method according to claim 14, wherein said IFN is administered daily or every other day.

27. (Previously presented) The method according to claim 14, wherein said IFN is administered twice or three times per week.

28. (Previously presented) The method according to claim 14, wherein said IFN is administered subcutaneously.

29. (Previously presented) The method according to claim 14, wherein said IFN is administered intramuscularly.

30. (Previously presented) The method according to claim 15, wherein the antiviral agent is administered at a dosage of about 100 to 2000 mg per person per day, or about 400 to 1200 mg per

person per day, or about 800 to 1000 mg per person per day, or about 1000 to 1200 mg per person per day.

31. (Previously presented) The method according to claim 16, wherein Ribavirin is administered orally.

32. (Previously presented) The method according to claim 14, wherein said method further comprises the administration of a composition comprising an antiviral agent to said individual.

33. (Previously presented) The method according to claim 32, wherein said composition is administered simultaneously, sequentially or separately from a composition comprising an IFN.

34. (Previously presented) The method according to claim 32, wherein said antiviral agent is Ribavirin.

35. (Previously presented) The method according to claim 34, wherein said antiviral agent is administered at a dosage of about 100 to 2000 mg per person per day, or about 400 to 1200 mg per person per day, or about 800 to 1000 mg per person per day, or about 1000 to 1200 mg per person per day.

36. (Previously presented) The method according to claim 35, wherein said antiviral agent is administered orally.

37 (New). The method according to claim 14, wherein said IFN is IFN- β 1A.

38 (New). The method according to claim 15, wherein said IFN is IFN- β 1A.